TLDR Baricitinib is effective and safe for treating alopecia areata in Korea.
This study evaluated the efficacy and safety of baricitinib in 117 Korean patients with alopecia areata (AA) over 36 weeks, showing significant hair regrowth with 55.4% of patients with severe AA achieving a SALT score of 20 or less. Patients with less severe AA experienced greater improvements. Adverse reactions were mild to moderate, affecting 16.8% of patients. The study concludes that baricitinib is a well-tolerated and effective treatment for treatment-resistant AA, with potential enhanced effectiveness when combined with therapies like corticosteroids and minoxidil. Further research is needed to assess long-term effects and compare with other treatments.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
3 citations
,
January 2023 in “JEADV Clinical Practice” IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
86 citations
,
January 2020 in “British Journal of Dermatology” The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
67 citations
,
January 2020 in “Cellular & Molecular Immunology/Cellular & molecular immunology” Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
